STAT3 and cancer: The key driving forces behind cancer (CSC) stem cells, including PI3K/AKT/mTOR and JAK/STAT3, had been shown to be highly regulated in high-CSC cancers, and clinical trials are being conducted to identify small molecules that target these pathways (Losuwannarak et al., 2019).